These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 2657279)

  • 1. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
    Walan A
    Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical utility and safety of omeprazole.
    Walan A
    Scand J Gastroenterol Suppl; 1989; 166():140-4; discussion 145. PubMed ID: 2574908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic achlorhydria: for which diseases, when and for how long?].
    Koop H; Arnold R
    Dtsch Med Wochenschr; 1988 Mar; 113(13):516-8. PubMed ID: 2894969
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G; Sabbatini F; Mazzacca G
    Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE; Jensen RT; Gardner JD
    Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Substituted benzimidazoles--a new dimension in ulcer therapy?].
    Fimmel CJ; Blum AL
    Wien Klin Wochenschr; 1984 Feb; 96(4):149-53. PubMed ID: 6324498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Omeprazole. Its pharmacology and therapeutic efficacy].
    Protzer U; Holtermüller KH
    Dtsch Med Wochenschr; 1993 Feb; 118(7):230-9. PubMed ID: 8440164
    [No Abstract]   [Full Text] [Related]  

  • 16. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Criteria for use of omeprazole in adult inpatients and outpatients.
    Lajoie C
    Clin Pharm; 1992 Feb; 11(2):177-9. PubMed ID: 1551300
    [No Abstract]   [Full Text] [Related]  

  • 18. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 19. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications and use of omeprazole in esophago-gastro-duodenal diseases].
    Martín de Argila C; Boixeda de Miquel D; Moreira Vicente V; García Plaza A
    Rev Clin Esp; 1999 Nov; 199(11):729-39. PubMed ID: 10638238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.